Prolong Completes Enrolling Patients in Phase 2 Trial of Sickle Cell Disease Therapy Sanguinate
Prolong Pharmaceuticals has completed enrolling patients in an ongoing Phase 2 clinical trial of Sanguinate, a treatment for the painful blocked blood vessel episodes that occur in sickle cell disease. ... Read more